WO2004002417A3 - Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations - Google Patents

Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations Download PDF

Info

Publication number
WO2004002417A3
WO2004002417A3 PCT/US2003/020347 US0320347W WO2004002417A3 WO 2004002417 A3 WO2004002417 A3 WO 2004002417A3 US 0320347 W US0320347 W US 0320347W WO 2004002417 A3 WO2004002417 A3 WO 2004002417A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
mammalian
specified portion
deleted
Prior art date
Application number
PCT/US2003/020347
Other languages
English (en)
Other versions
WO2004002417A2 (fr
Inventor
George A Heavner
David M Knight
John Ghrayeb
Bernard J Scallon
Thomas C Nesspor
Karen A Kutoloski
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to AU2003280130A priority Critical patent/AU2003280130B2/en
Priority to CA002490409A priority patent/CA2490409A1/fr
Priority to EP03742272A priority patent/EP1545608A4/fr
Priority to JP2004517981A priority patent/JP2006504406A/ja
Publication of WO2004002417A2 publication Critical patent/WO2004002417A2/fr
Publication of WO2004002417A3 publication Critical patent/WO2004002417A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne au moins un nouveau corps mimétique humain à délétion CH1 ou une partie spécifiée ou un variant de ce corps, et notamment des acides nucléiques isolés qui codent au moins un corps mimétique à délétion CH1 ou une partie spécifiée ou un variant de celui-ci, un corps mimétique à délétion CH1 ou une partie spécifiée ou des variants, vecteurs, cellules hôtes, animaux transgéniques ou plantes, ainsi que des procédés de fabrication et d'utilisation de corps mimétiques. L'invention se rapporte notamment à des compositions thérapeutiques, à des procédés et à des dispositifs associés.
PCT/US2003/020347 2002-06-28 2003-06-27 Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations WO2004002417A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003280130A AU2003280130B2 (en) 2002-06-28 2003-06-27 Mammalian CH1 deleted mimetibodies, compositions, methods and uses
CA002490409A CA2490409A1 (fr) 2002-06-28 2003-06-27 Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
EP03742272A EP1545608A4 (fr) 2002-06-28 2003-06-27 Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
JP2004517981A JP2006504406A (ja) 2002-06-28 2003-06-27 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39243102P 2002-06-28 2002-06-28
US60/392,431 2002-06-28

Publications (2)

Publication Number Publication Date
WO2004002417A2 WO2004002417A2 (fr) 2004-01-08
WO2004002417A3 true WO2004002417A3 (fr) 2004-11-04

Family

ID=30000868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020347 WO2004002417A2 (fr) 2002-06-28 2003-06-27 Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations

Country Status (6)

Country Link
EP (1) EP1545608A4 (fr)
JP (1) JP2006504406A (fr)
CN (1) CN1735433A (fr)
AU (1) AU2003280130B2 (fr)
CA (1) CA2490409A1 (fr)
WO (1) WO2004002417A2 (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1124961B9 (fr) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Composes thrombopoietiques
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2003084477A2 (fr) * 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
CN1890383A (zh) * 2003-09-30 2007-01-03 森托科尔公司 人铰链核心模拟体、组合物、方法和用途
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
EP1799700A4 (fr) 2004-09-27 2009-02-11 Centocor Inc Corps mimetiques srage, compositions, et methodes d'utilisation
MX2007004974A (es) * 2004-10-25 2007-10-17 Johnson & Johnson Mimeticuerpos que se unen al receptor de melanocortina, composiciones, metodos y usos.
MX2007011975A (es) * 2005-03-28 2008-03-14 Johnson & Johnson Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007115148A2 (fr) * 2006-03-31 2007-10-11 Centocor, Inc. Mimétiques de l'epo humaine à région centrale à charnière, compositions, procédés et utilisations dans la prévention ou le traitement de pathologies relatives à l'intolérance au glucose ou de l'anémie associée à une néphropathie
WO2008028044A2 (fr) 2006-08-30 2008-03-06 Centocor, Inc. Marqueurs et procédés pour évaluer et traiter la recto-colite hémorragique et des troubles associés utilisant un panel de 66 gènes
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
WO2008079982A2 (fr) 2006-12-21 2008-07-03 Centocor, Inc. Composition de liposome utilisée pour cibler le récepteur egf
WO2008079973A2 (fr) 2006-12-21 2008-07-03 Centocor, Inc. Peptides de liaison au récepteur egf et utilisations de ces derniers
WO2008092209A1 (fr) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protéine recombinée aux propriétés améliorées
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
EP3381445B1 (fr) 2007-11-15 2023-10-25 Amgen Inc. Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
EP2620448A1 (fr) 2008-05-01 2013-07-31 Amgen Inc. Anticorps anti-hepcidine et méthodes d'utilisation associées
ES2581774T3 (es) 2008-08-29 2016-09-07 Janssen Biotech, Inc. Marcadores y métodos de evaluación y tratamiento de colitis ulcerosa y trastornos relacionados mediante un panel de 20 genes
US20120052066A1 (en) 2008-11-07 2012-03-01 Cesar Calderon Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
JP6018753B2 (ja) 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
AU2010322205B2 (en) 2009-11-17 2015-01-22 Janssen Biotech, Inc. Improved bacterial membrane protein secretion
AU2010322202B2 (en) 2009-11-17 2015-01-22 Janssen Biotech Inc. Display of disulfide linked dimeric proteins on filamentous phage
EP2536435B1 (fr) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Homologue de singe d'interféron oméga humain
EP2558482B1 (fr) 2010-04-16 2017-09-27 Janssen Biotech, Inc. Protéases à cystéine végétales génétiquement modifiées et leurs utilisations
SG194370A1 (en) 2010-06-07 2013-11-29 Amgen Inc Drug delivery device
CA2812389C (fr) 2010-09-27 2019-12-31 John Kehoe Anticorps se liant au collagene humain de type ii
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
PT2699293T (pt) 2011-04-20 2019-05-21 Amgen Inc Aparelho de autoinjeção
AU2012322796B2 (en) 2011-10-14 2017-03-16 Amgen Inc. Injector and method of assembly
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
EP2968760B1 (fr) 2013-03-15 2024-01-03 Amgen Inc. Cartouche à médicament, auto-injecteur et système d'auto-injection
WO2014152006A2 (fr) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anticorps antihepcidine et leurs utilisations
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
LT2976117T (lt) 2013-03-22 2021-02-25 Amgen Inc. Purkštuvas ir surinkimo būdas
EP3501575B1 (fr) 2013-10-24 2021-12-01 Amgen Inc. Système de distribution de médicaments équipé d'un dispositif de commande sensible à la température
EP3789064A1 (fr) 2013-10-24 2021-03-10 Amgen, Inc Injecteur et procédé d'assemblage
WO2015119906A1 (fr) 2014-02-05 2015-08-13 Amgen Inc. Système d'administration de médicament doté d'un générateur de champ électromagnétique
CA2945026C (fr) 2014-05-07 2023-10-10 Amgen Inc. Auto-injecteur comprenant des elements de reduction de choc
CA2948003C (fr) 2014-06-03 2023-06-27 Amgen Inc. Systeme d'administration de medicament et son procede d'utilisation
CA2961917A1 (fr) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Anticorps anti-hepcidine humanises et utilisations de ceux-ci
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
CA2976935C (fr) 2015-02-17 2020-03-10 Amgen Inc. Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations
EP3261690B1 (fr) 2015-02-27 2021-12-15 Amgen Inc. Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (fr) 2016-03-15 2017-09-21 Amgen Inc. Réduction de la probabilité de casse du verre dans des dispositifs d'administration de médicament
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (fr) 2016-05-13 2017-11-16 Amgen Inc. Ensemble manchon de flacon
EP3458988B1 (fr) 2016-05-16 2023-10-18 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
EP3465124A1 (fr) 2016-06-03 2019-04-10 Amgen Inc. Appareils et procédés d'essai au choc destinés aux dispositifs d'administration de médicaments
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (fr) 2016-08-17 2018-02-22 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement.
WO2018081234A1 (fr) 2016-10-25 2018-05-03 Amgen Inc. Injecteur porté sur le corps
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
JP2020509837A (ja) 2017-03-09 2020-04-02 アムジエン・インコーポレーテツド 薬剤送達装置のための挿入機構
EP3570871B1 (fr) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Procédé de glyco-ingénierie in vitro d'une protéine de stimulation de l'érythropoïèse
LT3600491T (lt) 2017-03-28 2023-10-10 Amgen Inc. Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
EP3641857A1 (fr) 2017-06-22 2020-04-29 Amgen Inc. Réduction des impacts/chocs d'activation d'un dispositif
EP3641861A1 (fr) 2017-06-23 2020-04-29 Amgen Inc. Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing element for drug container and methods of assembly
WO2019022950A1 (fr) 2017-07-25 2019-01-31 Amgen Inc. Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
EP3664863A2 (fr) 2017-08-09 2020-06-17 Amgen Inc. Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567A1 (fr) 2017-08-18 2020-06-24 Amgen Inc. Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (fr) 2017-10-04 2023-02-08 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
EP4257164A3 (fr) 2017-10-06 2024-01-17 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (fr) 2017-11-03 2019-05-09 Amgen Inc. Systèmes et approches pour stériliser un dispositif d'administration de médicament
EP3706830A1 (fr) 2017-11-06 2020-09-16 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement et de débit
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
WO2020023444A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
US20210128844A1 (en) 2018-07-24 2021-05-06 Amgen Inc. Delivery devices for administering drugs
CA3103105A1 (fr) 2018-07-31 2020-02-06 Amgen Inc. Ensemble de trajet de fluide pour dispositif d'administration de medicament
AU2019347710A1 (en) 2018-09-24 2021-02-04 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (fr) 2018-09-28 2021-08-04 Amgen Inc. Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
WO2020072577A1 (fr) 2018-10-02 2020-04-09 Amgen Inc. Systèmes d'injection pour administration de médicament avec transmission de force interne
MA53818A (fr) 2018-10-05 2022-01-12 Amgen Inc Dispositif d'administration de médicament ayant un indicateur de dose
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
EP3866889A1 (fr) 2018-10-15 2021-08-25 Amgen Inc. Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
US20220031939A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
AU2020263289A1 (en) 2019-04-24 2021-09-16 Amgen Inc. Syringe sterilization verification assemblies and methods
EP4017560A2 (fr) 2019-08-23 2022-06-29 Amgen, Inc Dispositif d'administration de médicament doté de composants configurables de mise en prise de protection d'aiguille et méthodes associées
AU2022279223A1 (en) 2021-05-21 2023-10-19 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2024094457A1 (fr) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Procédé de production de compositions de glycoprotéines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US5169762A (en) 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4740587A (en) 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US4721672A (en) 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0832981A1 (fr) 1987-02-17 1998-04-01 Pharming B.V. Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement
EP0288088B1 (fr) 1987-04-24 1994-03-09 Teijin Limited Détection du facteur nécrosant de tumeur; anticorps monoclonal et composition
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5231166A (en) 1988-10-25 1993-07-27 Takeda Chemical Industries, Ltd. Endothelin
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DK0486526T3 (da) 1989-08-07 1996-06-24 Peptide Technology Ltd Bindingsligander for tumornekrosefaktor
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5210026A (en) 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5268465A (en) 1991-01-18 1993-12-07 The Johns Hopkins University Purification and molecular cloning of nitric oxide synthase
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
EP0575545B1 (fr) 1991-03-15 2003-05-21 Amgen Inc. Pegylation de polypeptides
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
US5976835A (en) 1992-03-19 1999-11-02 The Rockefeller University Nucleic acids encoding receptor recognition factor Stat1α and Stat1β, and methods of use thereof
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5315000A (en) 1992-05-14 1994-05-24 Children's Hospital Medical Center Gene encoding for a L5/3 growth factor and its CDNA
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
ES2127837T3 (es) 1992-10-19 1999-05-01 Dura Pharma Inc Inhalador para polvo seco.
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US6143289A (en) 1992-12-09 2000-11-07 Indiana University Foundation Compositions of myeloid-cell-suppressive chemokines
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
DE69414369T2 (de) 1993-01-19 1999-05-27 Glaxo Group Ltd Aerosol-spender und verfahren zu seiner herstellung
US6482919B2 (en) * 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP1978095A1 (fr) 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Transcription régulée de gènes ciblés et autres évènements biologiques
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US5767247A (en) 1994-11-11 1998-06-16 Noboru Kaneko Anti-annexin-V monoclonal antibodies, and preparation and use thereof
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6284535B1 (en) 1995-09-07 2001-09-04 The Trustees Of Columbia University In The City Of New York Splice variants of the heregulin gene, nARIA and uses thereof
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
CN1213974A (zh) 1996-01-03 1999-04-14 葛兰素集团有限公司 吸入器具
US5700774A (en) 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6271347B1 (en) 1996-04-26 2001-08-07 Merck & Co., Inc. Eosinophil eotaxin receptor
EP0911393B1 (fr) 1996-06-07 2007-01-10 Takeda Pharmaceutical Company Limited Peptide ayant une activité cortistatin ou somatostatin, procede de production et mode d'utilisation correspondants
DE69714698T2 (de) 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU4159197A (en) 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6030780A (en) 1996-10-15 2000-02-29 The Rockefeller University Purified Stat proteins and methods of purifying thereof
ES2293662T3 (es) 1996-11-15 2008-03-16 Genentech, Inc. Purificacion de neurotrofinas.
JP2001504830A (ja) 1996-11-19 2001-04-10 ジョージタウン ユニバーシティ ヘレグリン拮抗因子及びその利用方法
US5948892A (en) 1996-12-16 1999-09-07 Amgen Inc. Analogs of macrophage stimulating protein
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
IT1292017B1 (it) 1997-05-28 1999-01-25 Dompe Spa Composizioni farmaceutiche contenenti la proteina stimolante i macrofagi per il trattamento di patologie del sistema nervoso
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
AR016551A1 (es) 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1642910T3 (da) 2000-12-05 2012-05-07 Alexion Pharma Inc Rationelt designede atistoffer
CZ308214B6 (cs) * 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
WO2003084477A2 (fr) * 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOIDE A. ET AL: "The fibronectin type III domain as a scaffold for novel binding proteins", JOURNAL OF MOLECULAR BIOLOGY, vol. 284, 1998, pages 1141 - 1151, XP004455886 *
See also references of EP1545608A4 *
WU A.M. ET AL: "Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange", PROTEIN ENGINEERING, vol. 14, no. 12, 2001, pages 1025 - 1033, XP002982160 *

Also Published As

Publication number Publication date
EP1545608A2 (fr) 2005-06-29
CA2490409A1 (fr) 2004-01-08
AU2003280130B2 (en) 2009-06-11
EP1545608A4 (fr) 2006-09-13
AU2003280130A1 (en) 2004-01-19
WO2004002417A2 (fr) 2004-01-08
JP2006504406A (ja) 2006-02-09
CN1735433A (zh) 2006-02-15

Similar Documents

Publication Publication Date Title
WO2004002417A3 (fr) Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2003084477A3 (fr) Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
WO2005097175A3 (fr) Corps mimetiques glp-1 humains, compositions, procedes et utilisations
WO2005081687A3 (fr) Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
WO2005032460A3 (fr) Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes
LUC00121I2 (fr)
WO2008011446A3 (fr) Mimétiques de la glp-1 humaine, compositions, procédés et utilisations
WO2007046834A3 (fr) Agonistes glp-1, compositions, procedes et utilisations
WO2002072788A3 (fr) Proteines provenant de l'immunoglobuline associees a la bronchopneumopathie chronique obstructive, compositions, procedes et utilisations
WO2005005604A3 (fr) Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
WO2002012501A3 (fr) Anticorps anti-integrines doubles, compositions, procedes et utilisations associes
WO2002097048A3 (fr) Proteines derivees de l'immunoglobuline anti-p40, compositions, procedes et utilisations
WO2003086451A8 (fr) Proteines derivees de l'immunoglobuline anti il-13 associees a l'asthme, compositions, procedes et utilisations associes
WO2004003147A3 (fr) Polypeptides cngh0004, anticorps, compositions, procedes et utilisations
WO2006036745A3 (fr) Proteines derivees de l'immunoglobuline specifiques de il-23p40, compositions, epitopes, procedes et utilisations
WO2005062881A3 (fr) Therapie genique faisant intervenir des vecteurs de transposon
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
WO2004101750A3 (fr) Proteines derivees de l'immunoglobine specifiques de il-23p40, compositions, procedes et utilisations
WO2005028511A3 (fr) Anticorps anti-amyloides, compositions, procedes et utilisations
WO2003035847A3 (fr) Proteines muteines il-13, anticorps, compositions, procedes et utilisations
WO2006124451A3 (fr) Anticorps anti-il-13, compositions, procedes et utilisations
WO2004067567A3 (fr) Anticorps diriges contre le virus dengue, compositions, methodes et utilisations correspondantes
WO2007076319A3 (fr) Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations
WO2003057821A3 (fr) Proteines et anticorps mut-il-18 or mut-il-18r, compositions, procedes et utilisations
WO2003082206A3 (fr) Proteines derivees de l'immunoglobuline liees a la sclerose en plaques, compositions, methodes et utilisations relatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003280130

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2490409

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004517981

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003742272

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003742272

Country of ref document: EP